Marrone Bio Innovations Inc (NASDAQ:MBII): Philip Hempleman’s Ardsley Partners filed an amended 13D.
You can check out Ardsley Partners’ latest holdings and filings here.
Please follow Ardsley Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Ardsley Partners or update its stock holdings.
Follow Philip Hempleman's Ardsley Partners
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Ardsley Advisory Partners | 0 | 3,681,580 | 0 | 3,681,580 | 3,681,580 | 11.74% |
Philip J. Hempleman | 0 | 3,681,580 | 0 | 3,681,580 | 3,681,580 | 11.74% |
Ardsley Partners I | 0 | 3,631,580 | 0 | 3,631,580 | 3,631,580 | 11.58% |
Ardsley Partners Fund II | 0 | 595,300 | 0 | 595,300 | 595,300 | 1.90% |
Ardsley Partners Advanced Healthcare Fund | 0 | 1,189,700 | 0 | 1,189,700 | 1,189,700 | 3.79% |
Ardsley Partners Renewable Energy Fund | 0 | 1,846,580 | 0 | 1,846,580 | 1,846,580 | 5.89% |
Ardsley Duckdive Fund | 0 | 50,000 | 0 | 50,000 | 50,000 | 0.16% |
Follow Philip Hempleman's Ardsley Partners
Page 1 of 13 – SEC Filing
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G/A
Under
the Securities Exchange Act of 1934
Marrone Bio
Innovations, Inc.
(Name of Issuer)
Common Stock
(Title of Class
of Securities)
57165B106
(CUSIP Number)
December
31, 2017
(Date of Event
Which Requires Filing of this Statement)
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
x | Rule 13d-1(b) |
x | Rule 13d-1(c) |
o | Rule 13d-1(d) |
*The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior
cover page.
The information
required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
Persons
who are to respond to the collection of information contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 2 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 2 of 13 Pages |
1. | names of reporting i.r.s. identification no.
Ardsley Advisory | |||||
2. | check the appropriate box if a group* | (a) (b) | ||||
3. | sec use only
| |||||
4. | citizenship or place New York, | |||||
number of shares | 5. | sole voting power | 0 | |||
beneficially owned by | 6. | shared voting power | 3,681,580 | |||
each reporting | 7. | sole dispositive power | 0 | |||
person with: | 8. | shared dispositive power | 3,681,580 | |||
9. | aggregate amount beneficially owned by each reporting person | 3,681,580 | ||||
10. | check box if the aggregate amount in row (9) excludes certain shares (See Instructions) | o | ||||
11. | percent of class represented by amount in row (9) | 11.74% | ||||
12. | type of reporting person (See Instructions) | PN, IA |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 3 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 3 of 13 Pages |
1. | names of reporting i.r.s. identification no.
Philip J. Hempleman | |||||
2. | check the appropriate box if a group* | (a) (b) | ||||
3. | sec use only
| |||||
4. | citizenship or place United | |||||
number of shares | 5. | sole voting power | 0 | |||
beneficially owned by | 6. | shared voting power | 3,681,580 | |||
each reporting | 7. | sole dispositive power | 0 | |||
person with: | 8. | shared dispositive power | 3,681,580 | |||
9. | aggregate amount beneficially owned by each reporting person | 3,681,580 | ||||
10. | check box if the aggregate amount in row (9) excludes certain shares (See Instructions) | o | ||||
11. | percent of class represented by amount in row (9) | 11.74% | ||||
12. | type of reporting person (See Instructions) | IN |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 4 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 4 of 13 Pages |
1. | names of reporting i.r.s. identification no.
Ardsley Partners | |||||
2. | check the appropriate box if a group* | (a) (b) | ||||
3. | sec use only
| |||||
4. | citizenship or place New York, | |||||
number of shares | 5. | sole voting power | 0 | |||
beneficially owned by | 6. | shared voting power | 3,631,580 | |||
each reporting | 7. | sole dispositive power | 0 | |||
person with: | 8. | shared dispositive power | 3,631,580 | |||
9. | aggregate amount beneficially owned by each reporting person | 3,631,580 | ||||
10. | check box if the aggregate amount in row (9) excludes certain shares (See Instructions) | o | ||||
11. | percent of class represented by amount in row (9) | 11.58% | ||||
12. | type of reporting person (See Instructions) | PN |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 5 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 5 of 13 Pages |
1. | names of reporting i.r.s. identification no.
Ardsley Partners | |||||
2. | check the appropriate box if a group* | (a) (b) | ||||
3. | sec use only
| |||||
4. | citizenship or place Delaware, | |||||
number of shares | 5. | sole voting power | 0 | |||
beneficially owned by | 6. | shared voting power | 595,300 | |||
each reporting | 7. | sole dispositive power | 0 | |||
person with: | 8. | shared dispositive power | 595,300 | |||
9. | aggregate amount beneficially owned by each reporting person | 595,300 | ||||
10. | check box if the aggregate amount in row (9) excludes certain shares (See Instructions) | o | ||||
11. | percent of class represented by amount in row (9) | 1.90% | ||||
12. | type of reporting person (See Instructions) | PN |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 6 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 6 of 13 Pages |
1. | names of reporting i.r.s. identification no.
Ardsley Partners | |||||
2. | check the appropriate box if a group* | (a) (b) | ||||
3. | sec use only
| |||||
4. | citizenship or place Delaware, | |||||
number of shares | 5. | sole voting power | 0 | |||
beneficially owned by | 6. | shared voting power | 1,189,700 | |||
each reporting | 7. | sole dispositive power | 0 | |||
person with: | 8. | shared dispositive power | 1,189,700 | |||
9. | aggregate amount beneficially owned by each reporting person | 1,189,700 | ||||
10. | check box if the aggregate amount in row (9) excludes certain shares (See Instructions) | o | ||||
11. | percent of class represented by amount in row (9) | 3.79% | ||||
12. | type of reporting person (See Instructions) | PN |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 7 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 7 of 13 Pages |
1. | names of reporting i.r.s. identification no.
Ardsley Partners | |||||
2. | check the appropriate box if a group* | (a) (b) | ||||
3. | sec use only
| |||||
4. | citizenship or place Delaware, | |||||
number of shares | 5. | sole voting power | 0 | |||
beneficially owned by | 6. | shared voting power | 1,846,580 | |||
each reporting | 7. | sole dispositive power | 0 | |||
person with: | 8. | shared dispositive power | 1,846,580 | |||
9. | aggregate amount beneficially owned by each reporting person | 1,846,580 | ||||
10. | check box if the aggregate amount in row (9) excludes certain shares (See Instructions) | o | ||||
11. | percent of class represented by amount in row (9) | 5.89% | ||||
12. | type of reporting person (See Instructions) | PN |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 8 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 8 of 13 Pages |
1. | names of reporting i.r.s. identification no.
Ardsley Duckdive | |||||
2. | check the appropriate box if a group* | (a) (b) | ||||
3. | sec use only
| |||||
4. | citizenship or place Delaware, | |||||
number of shares | 5. | sole voting power | 0 | |||
beneficially owned by | 6. | shared voting power | 50,000 | |||
each reporting | 7. | sole dispositive power | 0 | |||
person with: | 8. | shared dispositive power | 50,000 | |||
9. | aggregate amount beneficially owned by each reporting person | 50,000 | ||||
10. | check box if the aggregate amount in row (9) excludes certain shares (See Instructions) | o | ||||
11. | percent of class represented by amount in row (9) | 0.16% | ||||
12. | type of reporting person (See Instructions) | PN |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 9 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 9 of 13 Pages |
Item 1. | |||||
(a) Name of Issuer: | Marrone Bio Innovations, Inc. | ||||
(b) Address of Issuer’s Principal Executive Offices: | 1540 Davis, | ||||
Item 2. | |||||
(a) Name of Person Filing: | This Schedule 13G/A (the “Schedule”) is being filed with respect to shares of Common Stock (as defined below) of Marrone Bio Innovations, Inc. (the “Issuer”) which are beneficially owned by Ardsley Advisory Partners (the “Advisor”), Ardsley Partners I (the “General Partner”), Phillip J. Hempleman (“Hempleman”), Ardsley Partners Fund II, L.P. (the “Fund II”), Ardsley Partners Advanced Healthcare Fund, L.P. (the “Healthcare Fund”), Ardsley Partners Renewable Energy Fund (the “Renewable Energy Fund”) and Ardsley Duckdive Fund, L.P. (the “Duckdive Fund”) (together, the “Reporting Persons”). See Item 4 below. | ||||
(b) Address of Principal Business Office or, if none, Residence: | 262 Stamford, | ||||
(c) Citizenship: | The Fund II, the Advanced Healthcare Fund, the Renewable Energy Fund and the Duckdive Fund are Delaware limited partnerships. The Advisor and the General Partner are New York general partnerships. Hempleman is a United States Citizen. | ||||
(d) Title of Class of Securities: | Common Stock | ||||
(e) CUSIP Number: | 57165B106 | ||||
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a) | o | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
(b) | o | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
(c) | o | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
(d) | o | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). |
(e) | x | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
(f) | o | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
(g) | o | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
(h) | o | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
(i) | o | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
(j) | o | Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 10 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 10 of 13 Pages |
Item 4. Ownership.
Provide the
following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item
1.
The Information
required by Items 4(a) – (c) is set forth in Rows 5-11 of the cover page for each Reporting Person hereto and is incorporated
by reference for each Reporting Person. The percentage ownership of the Reporting Persons is based on the 31,350,877 outstanding
shares of Common Stock of the Issuer, as disclosed on the Issuer’s 10-Q filed with the SEC on November 14, 2017.
Item 5. Ownership
of Five Percent or Less of a Class.
If this statement
is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following: o.
Item 6. Ownership
of More Than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification
and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not applicable.
Item 8. Identification
and Classification of Members of the Group.
See Exhibit
2
Item 9. Notice
of Dissolution of Group.
Not applicable.
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 11 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 11 of 13 Pages |
Item 10. Certification.
(a) | The By |
(b) | The
By |
(c) | The
By
|
(d) | The
By
|
(e) | The
By
|
(f) | The
By |
(g) | The
By |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 12 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 12 of 13 Pages |
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
January 26, 2018 | ||
Date | ||
ARDSLEY ADVISORY PARTNERS | ||
/s/ Steve Napoli | ||
Signature | ||
Steve Napoli/Partner | ||
Name/Title | ||
January 26, 2018 | ||
Date | ||
ARDSLEY PARTNERS I | ||
/s/ Steve Napoli | ||
Signature | ||
Steve Napoli/General Partner | ||
January 26, 2018 | ||
Date | ||
PHILIP J. HEMPLEMAN | ||
/s/ Steve Napoli* | ||
Signature | ||
Steve Napoli/Attorney-in Fact for Philip J. Hempleman | ||
Name/Title |
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Follow Marrone Bio Innovations Inc (NASDAQ:MBII)
Page 13 of 13 – SEC Filing
CUSIP No. 57165B106 | 13G/A | Page 13 of 13 Pages |
January 26, 2018 | ||
Date | ||
ARDSLEY PARTNERS FUND II, L.P. | ||
By: Ardsley Partners I, General Partner | ||
/s/ Steve Napoli | ||
Signature | ||
Steve Napoli/General Partner | ||
January 26, 2018 | ||
Date | ||
ARDSLEY PARTNERS ADVANCED HEALTHCARE FUND, L.P. | ||
By: Ardsley Partners I, General Partner | ||
/s/ Steve Napoli | ||
Signature | ||
Steve Napoli/General Partner | ||
January 26, 2018 | ||
Date | ||
ARDSLEY PARTNERS RENEWABLE ENERGY FUND, L.P. | ||
By: Ardsley Partners I, General Partner | ||
/s/ Steve Napoli | ||
Signature | ||
Steve Napoli/General Partner | ||
January 26, 2018 | ||
Date | ||
ARDSLEY DUCKDIVE FUND, L.P. | ||
By: Philip J. Hempleman, General Partner | ||
/s/ Steve Napoli* | ||
Signature | ||
Steve Napoli/ Attorney-in Fact for Philip J. Hempleman |
*
Executed by Steve Napoli as Attorney-in-Fact for Philip J. Hempleman. The Power of Attorney for Mr. Hempleman is attached as Exhibit
2 to the Statement on Schedule 13G/A with respect to the Common Stock of Vaxgen, Inc., filed on February 15, 2006, and is incorporated
herein by reference.
The original
statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement
is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing
person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided,
however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
NOTE:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
§240.13d-7 for other parties for whom copies are to be sent.
Attention: | Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) |